Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.72 ▲ +0.09
(+3.42%)
MKT CAP: $814.3M • VOL: 3.31M
52W L $2 52W H $5
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
SANA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$250.3M | -$272.7M | -$293.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$244.2M | -$266.8M | -$283.3M |
| EBITDA (Normalized) | -$249.6M | -$246.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$143.8M | -$223.2M | -$253.6M |
| Capital Expenditures (CapEx) | $938.0K | $33.4M | — |
| Free Cash Flow (FCF) | -$144.8M | -$256.6M | -$253.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $71.9M | $127.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $160.9M | $250.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SANA.